Polyrizon's Allergy Blocker Trial Receives Central IRB Approval, Advancing Towards Patient Enrollment
PLRZ has more than doubled off its 52-week low of $2.88 on light trading volume (0.1× avg).
Summary
Polyrizon has received central Institutional Review Board (IRB) approval for its NASARIX™ Allergy Blocker clinical trial. This critical regulatory milestone confirms the study protocol and patient protection requirements are met, following the company's recent announcement of securing three major U.S. clinical sites. For a development-stage biotech, this approval is a significant step towards initiating human trials and de-risking its lead product. Individual clinical sites still require separate approvals before patient enrollment can commence.
At the time of this announcement, PLRZ was trading at $11.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.9M. The 52-week trading range was $2.88 to $18.20. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.